Background and Purpose. Evaluation of physical therapy for gait disorders in patients with Parkinson's disease (PD) requires an understanding of how the patients' medication cycle affects function. Four experiments were conducted to investigate stability of gait variables. Methods and Results. In experiment 1, 15 subjects with idiopathic PD and 15 subjects without PD performed two sets of gait trials spaced 30 minutes apart, with the initial trial conducted with the subjects at a peak dose of medication. Strong correlations, as determined by intraclass correlation coefficients (1CC[2,1]), occurred between repeat measures of speed (ICC= .92), cadence (ICC= .92), stride length (IC:C=.94), and time spent in double support (DS) (ICC=.Y3) . In experiment 2, 16 subjects with PD were tested at the same time on two consecutive days. There was good repeatability for speed (ICC=.88), cadence (ICC=.85), stride length (ICC= .84), and DS (ICC= .80). When we assessed the repeatability of measurements taken at peak dose and at end of dose, there were low correlations for speed (ICC= -.54), cadence (ICC= -.07), stride length (ICC= -.S5), and DS (ICC= -..38). In a final experiment on 16 subjects with PD, we used time-series analysis to examine the stability of measurements taken every 15 minutes for 2% hours. Slopes of regression models, standard deviations, and residual autocorrelations were negligible, indicating that the measurements were stable.
diopathic Parkinson's disease (PD) is a chronic neurological condition characterized by a progressive depletion of doparninergic neurons in the brain-stem nuclei and a reduction in dopamine receptor sites in the striatum.1 Motor fluctuations frequently emerge as the disease advances, particularly as the response to pharmacological therapy becornes more variable. ' The majority of people with idiopathic PD initially respond very favorably to parkinsonian medication; however, it is common for motor fluctuations to occur after 5 years or more of dopamine-replacement therapy.'-4 The swings in motor performance associated with changing levels of dopamine uptake can result in disabling bouts of akinesia, hypokinesia, rigidity, dyskinesia, and dystonia. In turn, these movement disorders can lead to disability and handicap."
The variability in motor performance associated with advanced idiopathic PD is well documented for disorders of upper-limb movement and affects the individual's ability to perform handwriting, prehension, and pegboard tasks.k7 Studies on cortical brain potentials prior to upper-limb movement demonstrate that activity in the motor cortical regions varies according to levodopa d o~a g e .~
The degree to which locomotor control fluctuates throughout the day or from one day to the next, however, remains uncertain. In addition, the stability and repeatability of gait measurements at different stages of the medication cycle has been poorly documented. In order to evaluate the effect5 of service provision, clinicians require reliable and valid measures of change in the gait pattern. They also need to have a nlodel of' gait stability against which changes in performance with treatment can be compared.
The need for reliable measures of gait stability is particularly important for the spatiotemporal variables, which provide a direct measure of the short-stepped, highcadence walking pattern that is characteristic of idiopathic PD.".l(' Spatiotemporal measures quantify distance and time aspects of the footstep pattern such as the walking speed, cadence (steps per minute), stride length, and proportion of the gait cycle spent in the double-limb-support phase (DS), in which both feet are in contact with the ground. Additional measures that have been used to quantifji parkinsonian gait include joint kinematics"-l3 and electromyographic activity of There has been little attempt, however, to establish the repeatability and stability over time of these gait measures in subjects with measures in PDk7 have yielded somewhat equivocal I PD. Two studies of the repeatability of spatiotemporal results. Bowes et alc' reported low product-moment correlation coefficients for repeatability of measures of walking speed (r=.24), stride length (~. 2 4 ) , cadence (7=.36), and mean DS (r=.25) in subjects with idiopathic PD. In contrast, Stern et a17 reported finding highly significant correlations between paired observations for walking speed and stride length but gave n o values for these correlations. Different methodologies, however, were used for these two investigations. Stern et a1 made repeat determinations of the gait pattern between 1 and 4 weeks after the initial test using a metal walkway system. They did not report reliability coeffii cients or document the locus of the gait cycle in which measures were taken. Bowes et a1"xamined the gait pattern six times using a gait-assessment trolley following omission of a morning dose of levodopa. A 5-111 length of cotton attached to the sultjects' heels and attached to geared pinch wheels of the gait assessment trolley enabled the footstep variables to be documented, and the output was displayed o n a chart recorder. The encumbrance of the cotton might have increased t l~e error variance of the gait measures. In addition, the gait traces from the chart recorder were measured by hand, which the authors acknowledged could have reduced reliability. Alternatively, omission of the morning levodopa dose might have produced motor fluctl~ations.
Related studies on the response of parkinsonian gait to levodopa have shown variability of performance according to the subjects' medication status."'-'-' Pedersen et al," fbr example, found that gait speed and stride length decreased markedly on withdrawal of parkinsonian medication, whereas changes in the walking cadence (steps per minute) were negligible. Blin et a12" tested subjects with PD before and 1 hour after the administration of le~rodopa and found that gait speed and stride length were dopa-sensitive and that cadence did not change. These results suggest that control of stride length and gait speed might be mediated by dopamine, whereas the regulation of walking cadence might be under the control of nondopan~inergic systems.
The findings of Blin e t a12" and Pedersen et a F 3 indicate that stride length and gait speed vary according to levodopa levels. Whether meaningful fluctuations in stride length, gait speed, or even cadence occur within a medication cycle is not known. Whether there is variation in the parkinsonian gait pattern from day to day also is not known.
The purpose of our four experiments was to investigate the stability over time of the locomotor pattern in patients with PD. The aim of the first experiment was to examine the ~rpeatability of gait measurements taken 2 minutes and 30 minutes apart when subjects were at peak dose of medication (on average, 60 minutes after the medication was taken). In the second experiment, we evaluated the difference between gait measurements taken at the same time on consecutive days when s u b jects were at peak dose. The purpose of the third experiment was to investigate the effects of medication status o n the gait pattern by assessing the repeatability of gait measurements taken from peak dose to end of dose, when motor fluctuations are most likely to emerge. The aim of the final experiment was to determine the stability of gait measurements taken over a longer time period within a medication cycle. Because physical therapy is typicallv provided within a 2-to 3-hour time frame when patients are i11 the "on" phase of the medication cycle, we measured the gait pattern approximately every 15 minutes over a 165-minute period at peak dose. A proportion of the data analyzed in these experiments was used previously to investigate the pathogenesis of gait hypokinesia in persons with PD.' "' ln addition, the resl~lts of experiment 4 provide a more detailed anal>,sis of individual subject data obtained from a recent ~t u d y of stride-length regulation in patients with PD.'+
Method

Subjects
Forty-four subjects were recruited from inpatient facilities, the Movement Disorders Clinic, and the V o l~n~t e e r Services Unit of the Kingston Centre (Cheltenham, Victoria, Australia). There were 15 subjects with PD and 15 control subjects in the first experiment, 16 snbjects with PD in the second experiment, 12 snbjects with PD in the third experiment, and 16 subjects with PD in the final experinlent. Tables 1 through 4 provide a summary of the characteristics of the subjects with PD and show that some subjects participated in more than one experiment.
T o be included ill the investigation, subjects were required to be 60 to 85 years of age, to be able to walk a 10-m distance repeatedly without assistivc de\ '~ces ' or assistance from another person, and to be able to provide informed consent according to the Declaration of Helsinki (1964). Subjects were excluded ~f they had neurological conditions other than idiopathic PD. as determined by a neurologist. S~lbjects also were excluded if they had visual impair~nent or niusculoskeleta1 o r cardiovascular disorders that affected loco~~iotion or if they scored less than 20 on the Short Test of Mental Status (STMS)."' The STMS is a cognitive test that allows -subjects to be screened for dementia, short-term memory disorders, and problenl-solving and planning deficits and has been validated previo~isly by Kokmen and colleagues." The total score obtainable on the scale is 38, and scores less than 20 are thought to indicate the presence of dementia. Subjects with severe lower-limb dyskinesia or dystonia were excluded because these movement disorders prevented using the footswitch system. The presence of dyskinesia or dystonia would be expected to lead to excessive movement disorders that would decrease the reliability of test scores. Thus, the retest reliability of measurements of gait variables in subjects with dyskinesia o r dystonia is considered to warrant independent analysis in a subsequent investigation, when suitable instrumentation for enabling data collection in subjects with these conditions is available.
All subjects were tested while they were taking their parkinsonian medication, although the time in the niedication cycle at which testing occurred varied according to the aims of the experiment. In general, subjects with PD were judged by a physical therapist and a ~~eurologist to be in the "on" phase of the medication cycle when they were able to move freely, easily, and quickly without In experime111 1, subjects with PD were tested on average 1.0 hoi~rs (SD=0.25, range=0.3-1.5) after their midmorning dose of medication, when they were judged by a physical therapist or a neurologist to have an effective response and to be in the "on" phase of the medication cycle.
The final sample for e s p e r i~n e~i t 1 consisted of 15 In exprriment 2 , there were 6 women and 10 men with sul?jects with PD (6 Inen, 9 women) and 15 control PD. The strbjects' mean age was 74.1 years (SD=5.6. st~t?jt.cts ( t i nlell, 9 wu11le11). I'he lliean age was 72.2 years ra1ige=64-82), their rnean height was 1.65 m (SD=0.85, range=1.51-1.78), and their mean body weight was 68.6 kg (SD= 11.1, rangez49-85). For this experiment, the mean Webster scaleX6 score was 14.1 (SD=4.4, range=7-24), and the mean score on the STMS was 29.1 (SD=3. 34. range=23-34) . Subjects with PD were tested on average 1.0 hours (SD=0.8, rangc=0.5-1.25) after their midmorning dose of medication o n the first day, and they were tested on average 1.0 hours (SD=0.7, range=0.5-1.25) after taking their medication on the second day.
(SD=0.076, range = 1.53-1.80), and their mean body weight was 63.3 kg (SD=9.0, range=53-78). The mean
Webster scalex%core was 13.3 (SD=2.6, range =7-18) in the "on" phase of the medication cycle and 15.33 (SD=2.4, range= 12-19) in thc "off' phase of the medication cycle. The mean SRMS score in the "on" phase was 27.3 (SD=3.6, range='ll-33). The subjects were tested on average 1.0 hours (SD=O.l, range=0.5-1.5) after their midmorning dose of medication and then on average 0.5 hours prior to the next dose of medication.
111 experiment 3, there were seven men and five women In experiment 4, there were nine men and seven women with PD. The sitbjects'mean age was 70.1 years (SD=5.9, with PD. The subjects' mean age was 72.75 years range=63-81), their mean height was 1.66 m (SD=5.07, range=64-81), their mean height was end and o n the sides of the walkway.
Apparatus
The gait patterns of the subjects with PD and the control subjects were measured using the Clinical Stride Analyzer.* The stride analyzer enables measurement of temporal footstep variables such as walking speed (measured as the time taken to walk a set distance), cadence (steps per minute), and DS. It also allows the stride length (length of two consecutive steps) to be derived. This system, which has been described previously in morc d~tail,",'~' consists of a pair of footswitches worn as innersoles within the shoes, a lightweight portable data logger worn as a backpack, and a personal computer. At the beginning and end of each 10-rn walking trial, the researcher (MEM) activated a hand-held trigger attached to the data logger to signal the commencement and termination of data collection. The gait data were analyzed using PCSA software, version 1 . 0 6 .~
Procedure
The general procedure for gait analysis will be described, and then the procedural details of each experiment will be detailed. In each of the experiments, the subjects were tested on a modified Webster scale2"y a neurologist and were given the S T M P h y a physical therapist. Footswitches of appropriate size were fitted inside cach subject's shoes, and the backpack was attached to the waist belt. The leads from the footswitches and the data-collection trigger were attached to the backpack. The subject was instructed to walk for a short period of time to accommodate to the apparatus and to identify any problems in footswitch fit. The subject was then instructed to "walk at a comfortable pace" down the gait walkway. The researcher walked 0.5 m behind the subject and activated the trigger at the beginning and end of rhe middle 10 m of each 12-111 walk. After each trial, the subject walked back to the con~puter and the data were transferred from the backpack to the computer for further analysis. was thcn instructed to sit down and have a brief rest. One 10-m practice trial preceded data collection for each of the conditions. After each reliability trial, the footswitches were removed from the shoes. The minimum number of steps over which the data were averaged was 15 sttrps for the subjects with PD and 20 steps for the control subjects.
In experiment 1 , 15 subjects with PD and 15 co~ltrol subjects matched for age, gender, and height pel-formed two sets of two gait tr-ials, with 30 minutes between sets. For this experiment, the first gait trial for subjects with PD was conducted on average 60 minutes after the midmorning dose of parkinsonian medication, when the subjects were judged to be at peak dose (the "on" phasc of the medication cycle).
In experiment 2, a different group of 16 subjects with PD
and matched control subjects were tested on average 60 minutes after the midmorning dose of medication, when they were judged to be in the "on" phase, and at the same time on the next day. The next dose of medication was scheduled 011 average 3 hours later. In this experiment, data from two consecutive gait trials performed 2 minutes apart on each day were analyzed.
The a i~n of the experinlent 3 was to compare the retest reliability of gait measurements obtained at peak dose and at end of dose. In this experiment, 12 subjects walked at their preferred speed at optimal coverage of medication and 30 minutes prior to thc next dose, when rnotor fluctuations should be most severe. O n average, the interval between "on" and "off' measures was 2% confidence interval (CI) for individual change scores hours.
(95% CI = D ? X SDdill).
In experiment 4, we examined the repeatability of gait measurements obtained every 15 minutes over a 2%-hour period commencing 30 minutes after peak dose in 16 subjects with PD. This comparison enabled us to monitor the extent of motor fluctuations over a more extended period.
Spatial and Temporal Gait Variables
Measurements of the following gait variables were obtained for each subject on all trials: gait speed (in meters per minute), cadence (in steps per minute), stride length (in meters), and DS (expressed as a percentage of the gait cycle).
Statistical Analysis
The primary aim of the first three experiments was to investigate the repeatability of gait measures across two trials interspersed at different loci within the medication cycle. We therefore summarized the means and standard deviations for each of the dependent variables for each test and then examined the distribution of change scores over specified time intervals for each gait variable. Paired t tests were used to determine whether systematic change i r i each gait variable was statistically significant. Variable change was estimated by obtaining the standard deviation of the change scores (SD,;,) and the 95% 
Results
The means, standard deviations, and correlation coefficients for the pretest and posttest measures for each of the dependent variables in the first three experiments are presented in Tables 5 through 10 . The change scores fionl the pretest to the posttest measures for each of the experiments are illustrated by a series of box plots in Figures 1 through 4 . Box plots enable the median values of the change scores, the loth, 25th, 75th, and 90th percentiles, and the outliers to be displayed, which is important for the interpretation of data that are not normally distributed.
Experirnen t 1
The results of experiment 1 indicated that for repeat measures taken at 2-minute and 30-minute intervals, there was strong temporal stability of measures of walking speed, cadence, stride length, and DS (Figs. 1-4) . As shown in Tables 7 and 8 , the ICCs for the repeat deter~ninations ranged from .71 to .94 for the subjects with PD and from .93 to .99 for the control subjects. For the subjects with PD, the differences between repeat determinations for each of the comparisons were not statistically significant. For the control subjects, paired t tests revealed an increase in cadence for the 2-minute test and increases in walking speed, cadence, and stride length for the 30-minute test. For the 30-minute test, the standard deviations for the change scores for the control subjects were less than 3.5 steps/min for cadence, less than 0.03 m for stride length, and less than 2.5 m/min for speed.
We believe that the 95% GIs for each of the change scores for the 2-minute and 30-minute tests were within clinically acceptable limits, as shown by Figures 1  through 4 . In addition, Figures 1 through 4 illustrate that the (:I limits for all of the variables in both groups were narrower for the 30-minute test than for the 2-minute test. This finding was probably because only one gait trial was conducled for the pretest and posttest measures for the %minute test, whereas the mean of two consecutive gait trials was used for the pretest and posttest comparisons in the 30-minute test. The effect of averaging two trials was to reduce the standard deviation of' the change scores. Therefore. even though the mean : change was similar in the 2-minute and 30-minute tests, the limits of the GIs were smaller in the 30-minute test than in the 2-minute test.
. Morris et a1
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The results of experiment 2 showed stability in parkinsonian gait over a 24hour period when subjects were tested at the same locus of thc medication cycle. As with the first experiment, the means and standard deviations for walking speed and stride length in the s~tbjects with PD indicated that these variables were stable from one day to t l~e next (Tab. 9). None of the changes in gait variables were statistically significant.
Experiment 3
The ICCs for the repeat determinations from peak dose to end of dose in the subjects with PD ranged from -.54 to -.07 (Tab. l o ) , indicating an extremely poor degree tions were large for each of the variables (Figs. 1-4) . In the median, 25th and 75th percentiles (box limits), 10th and 90th addition, the upper and lower 95% CIS were very broad percentiles (whiskers], and outliers (circles). PD=subiects with Parkinfor walking speed, cadence, stride length, and DS.
son's disease; C=control subiects. 
Test Interval
Experiment 4
The time-series analyses condrlcted over a 2%-hour period indicated little change in performance for ally of the dependent variables during the "on" phase of medication in the majority of subjects. Visual inspection of the results f01-each individual suggested that a linear model could be fitted to the data. As documented in the group analyses by Morris et al,'-' the regression analyses obtained intercepts of 0.9420.15 for stride length, 103.3820.45 for cadence. and 36.2025.60 for DS, using group mean values ( 2 1 SD) to summarize the results. Similarly, the slopes were -0.00001 ?0.001 for stride length, 0.2220.85 for cadence, and 0.005-CO.02 for DS. Table 11 presents the slope and intercept values from the regression analysis for each subject with PD. Figure 5 illustrates the time series for stride length, cadence, and DS for subject 9, the characteristics of which were representative of 13 of the 16 subjects measured. The figure also illustrates the time series for each variable for an individual with greater variability of performance (s~lbjec~: 12). These data were representative of 3 of the 16 subjects. For this individual, the data could still be fitted using a linear model, and the standard deviation of the residuals was small for stride length (0.009), cadence (2.78), and DS (1.95). 0 1 1 occasions, the resid~~als appeared not to be entirely con~posed of random fluctuations around the line of best fit. The nonlinear residual, however, was of very small magnitude, in comparison with the differe~lces in performance between sul?jects with PD and control subjects or in comparison with changes in patient per-fo~.mance previously reported for intenrentions such as physical therapy."~") In addition, no autocorrelation in the residuals from linear regression was fbund. Box plot for change in cadence for experiments 1 to 3. PD=subjects with
Parkinson's disease; C=control subjects.
Discussion
In this investigation, we documented the temporal stability of the walking pattern in subjects with idiopathic PD at different loci within the medication cycle and from one day to the next. The basic gait pattern exhibited by the subjects with PD in experiments 1 , 2, and 4 was stable over time and was very similar to that previously reported for parkinsonian gait during the "on" phase of medicat i o~~.~,~-I .~. l ! )~~ Compared with the gait pattern of the control subjects, the gait of the subjects with PD was very slow, with short strides and greater time spent with both feet in contact. with the ground. The cadence values of the subjects with PD were similar to normal values in the majority of cases, despite reports in the literature that subjects with PD have a short-str-ide, high-cadencc patOur results probably reflect the finding that the subjects with PD walked at slower ftee speeds. In comparison with reports of cadence rates for slow walking speeds in asy~nptomatic elderly people,:"),:" the error and the random error of measurement and provide the clinician with the upper and lower limits of the range of change scores due to measurement error. To give an example, the 95% CIS for the 30-minute test in the first experiment indicated that for subjects with PD, the stride length would need to increase by more than 0.10 m between two consecutive measurements for the change to represent real improvement rather than measurement error. Likewise, the stride length would need to decrease by more than 0.09 m between two consecutive measurements to reflect a decrease in stride length that is not simply due to measurement error. Given that changes in stride length in subjects with PD with interventions such as physical therapy have been reported in the range of 0.5 to 1.0 m,"I0 the level of measurement error indicated by the CIS could be considered to be negligible.
In agreement with the reliability study conducted by Stern et al,7 the results of experiment 2 indicated a high degree of repeatability for measures of walking speed, stride length, and DS from one day to the next when subjects with PD were measured at the same time of day during the "on" phase of the medication cycle. Intraclass correlation coefficients ranged from .80 for DS to .88 for walking speed.
In experiment 3, the ICCs for repeat determinations from peak dose to end of dose ("on" versus "off' values)
showed a low degree of correlation (ICC= -.54 to -.07) and the change scores for each of the variables were l a r~e .
Given the consistencv of results of the other three Parkinson's disease; control s;biects.
than error introduced by the measurement apparatus or cadence rates for the subjects with PD are higher than nornlal when speed of walking is taken into account.
The results of experiment 1 indicated that parkinsonian gait is stable from the period commencing on average 60 ~ninutes postmedication to periods 2 minutes and 30 minutes later. In the subjects with PD, the ICCs for each of the deperlde~lt variables ranged from .71 to .94, indicating modelate to good repeatability. In the control subjects, the ICCs for repeat determinations obtained at 2 min~ltes and 30 minutes from the pretest were high, ranging from .!I3 to .99. As indicated by Figures 1 t h r o~~g h 4, the median values and CIS for the change scores werc relatively small for each of the variables in both groups.
The 95% CIS for the change scores also suggested that the gait patterns of the subjects with PD were stable over time, provided that the subjects were in the "on" phase of medication. The CIS account for both the systematic the procedures used. These results are similar to those of Bowes et who reported product-moment correlation coefficients of .24 to .36 following omission of a morning dose of levodopa medication. Both investigations suggest that with apparent depletion of medication, more variable changes occur in subjects with PD.
In experiment 3, the 95% CIS about the change scores for stride length from peak close to end of dose indicated that changes greater than 0.50 m would be needed to conclude that irlterventions such as physical therapy have an effect o n stride length in addition to the effects of medication and measurement error. Similarly, stride length would have to decrease by more than 0.90 m with training to reflect de~erioration not attributable to the effects of pharmacological therapy and measurement error. Mirroring these results, the 95% CIS about the change scores for walking speed and cadence for repeat determinatiorls obtained from peak dose to end of dose were very large. Persons with PD would have to increase their speed of walkirlg by more than 33 m/min for changes to be greater than the effects of measurement In experiment 4, we demonstrated that during a 165-minute period after levodopa was administered, the majority of subjects with PD maintained a very stable gait pattern. There were negligible slopes on linear regression analysis, and examination of the degree of autocorrelation in the residuals from linear regression revealed only minor fluctuations in performance that were not statistically significant. These findings indicate that in the period when physical therapy is usually provided, the gait pattern remains stable. Marked changes that occur concomitant with physical therapy during this period, therefore, are likely to be due to therapeutic processes rather than random variability associated with the locus of the medication cycle.
There are, however, a number of limitations in our investigation. Most notably, the sample sizes used in each of the experiments were relatively s~nall, ranging from a minimum of 12 to a maximum of 16. In addition, only subjects who could perform a series of 10-m gait trials without assistive devices or without any help from another person were included. The sample, therefore, did not include people who were severely affected by PD, as the Webster scale2" scores indicate. Subjects with dystonia and dyskinesia were also excluded from the sample. Furthermore, the focus of the investigation was on impairmelit variables such as gait speed and stride length rather than on functional variables such as gait endurance, maximum walking distance, or energy expendit~~re during ambulation. These factors limit the generalizability and application of the findings.
A number of implications for clinical practice, however, can be derived from our study. The results suggest that when evaluating the effects of interventions such as physical therapy for persons with PD, repeat assessments of the walking pattern at peak dose will be much more reliable than assessments that incorporate a pretest measure during the first 2% hours after levodopa medication and a posttest measure in the half hour prior to the next dose. The high level of random variability in repeat measures from the "on" phase to the "off' phase of the medication cycle suggests that repeat measures of this tvpe should be avoided.
The results indicate that patient performa~~ce fluctuates within a medication cycle and that even at peak dose of medication the walking pattern is not completely normal. This finding might signal the need for movement rehabilitation strategies to augment the beneficial effects of pharmacological therapy, particularly at the end of dose of medication when the walking pattern can he markedly hypokinetic and akinetic. Current strategies for movement rehabilitation in persons with PD are documented in the summaries by S~henkman,:~' Turnbull,sg Banks,:34 and Morris et aLS5
The results of experiment 1 highlighted that the standard deviation, and thus the CIS about the change scores, are reduced when the mean of two or more gait trials is used to evaluate change in performance, rather
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Figure 5.
Time series for stride length, cadence, and percentage of the gait cycle spent in doublelimb support (DS) after medication for two subjects in experiment 4.
-2- 
Conclusions
The results of this investigation have shown a high degree of stability over time and good repeatability within a session and from one day to the next for gait speed, stride length, and DS measured using a footswitch system, provided that subjects with PD were in the "on" phase of the medication cycle. In marked contrast, the repeatability of measures from peak dose to end of dose was very poor, and there was considerable deterioration in performance at the end of dose. These findings may not be surprising to physical therapy clinicians who specialize in the management of PD; however, they provide the first comprehensive, quantitative, and controlled confirmation of the temporal stability of the walking pattern at different loci within the medication cycle. 
